A. Spiros

发表

Semi-mechanistic computer simulation of psychotic symptoms in schizophrenia with a model of a humanized cortico-striatal-thalamocortical loop

H. Geerts, A. Spiros, P. Roberts, 2017, European Neuropsychopharmacology.

A computer-based quantitative systems pharmacology model of negative symptoms in schizophrenia: exploring glycine modulation of excitation-inhibition balance

H. Geerts, A. Spiros, P. Roberts, 2014, Front. Pharmacol..

A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson’s Disease

Hugo Geerts, Athan Spiros, H. Geerts, 2016, Front. Pharmacol..

Simulating the Effects of Common Comedications and Genotypes on Alzheimer's Cognitive Trajectory Using a Quantitative Systems Pharmacology Approach.

H. Geerts, A. Spiros, 2020, Journal of Alzheimer's disease : JAD.

Phosphodiesterase 10 inhibitors in clinical development for CNS disorders

H. Geerts, A. Spiros, P. Roberts, 2017, Expert review of neurotherapeutics.

Phenotypic screening of the Prestwick library for treatment of Parkinson's tremor symptoms using a humanized quantitative systems pharmacology platform.

H. Geerts, A. Spiros, P. Roberts, 2013, Journal of Parkinson's disease.

NEW INSIGHTS INTO HUMAN BRAIN AMYLOID KINETICS FROM A HUMANIZED COMPUTER MODELING STUDY

H. Geerts, A. Spiros, 2014, Alzheimer's & Dementia.

Quantitative systems pharmacology as an extension of PK/PD modeling in CNS research and development

H. Geerts, A. Spiros, P. Roberts, 2013, Journal of Pharmacokinetics and Pharmacodynamics.

Learning from amyloid trials in Alzheimer's disease. A virtual patient analysis using a quantitative systems pharmacology approach

H. Geerts, A. Spiros, 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.

Understanding responder neurobiology in schizophrenia using a quantitative systems pharmacology model: Application to iloperidone

S. Potkin, H. Geerts, A. Spiros, 2015, Journal of psychopharmacology.

Toward Predicting Impact of Common Genetic Variants on Schizophrenia Clinical Responses With Antipsychotics: A Quantitative System Pharmacology Study

H. Geerts, A. Spiros, 2021, Frontiers in Neuroscience.

A Quantitative System Pharmacology Computer Model for Cognitive Deficits in Schizophrenia

H Geerts, H. Geerts, A Spiros, 2013, CPT: pharmacometrics & systems pharmacology.

A strategy for developing new treatment paradigms for neuropsychiatric and neurocognitive symptoms in Alzheimer’s disease

H. Geerts, A. Spiros, P. Roberts, 2013, Front. Pharmacol..

Not all partial dopamine D2 receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse

Hugo Geerts, Robert Carr, Athan Spiros, 2010, Neuropsychiatric disease and treatment.

Neurons: Role of Ca Neurotransmission in Rat Neostriatal Projection Cholinergic Control of Firing Pattern and

J. Bargas, P. Rueda-Orozco, E. Galarraga, 2015 .

Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action

Hugo Geerts, Athan Spiros, Patrick D Roberts, 2012, Alzheimer's Research & Therapy.

Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model

H Geerts, H. Geerts, T. Comery, 2014, CPT: pharmacometrics & systems pharmacology.

Towards the virtual human patient. Quantitative Systems Pharmacology in Alzheimer's disease.

Hugo Geerts, Robert Carr, Athan Spiros, 2017, European journal of pharmacology.

A quantitative systems pharmacology study on optimal scenarios for switching to paliperidone palmitate once-monthly

H. Geerts, L. Alphs, A. Spiros, 2018, Schizophrenia Research.

Impact of amyloid-beta changes on cognitive outcomes in Alzheimer’s disease: analysis of clinical trials using a quantitative systems pharmacology model

H. Geerts, A. Spiros, P. Roberts, 2018, Alzheimer's Research & Therapy.

Systems pharmacology modeling in neuroscience: Prediction and outcome of PF-04995274, a 5-HT4 partial agonist, in a clinical scopolamine impairment trial

Hugo Geerts, Timothy Nicholas, Robert Carr, 2013 .

Nicotinic receptor modulation: advantages for successful Alzheimer's disease therapy.

H. Geerts, A. Spiros, R. Carr, 2002, Journal of neural transmission. Supplementum.

Blinded Prospective Evaluation of Computer-Based Mechanistic Schizophrenia Disease Model for Predicting Drug Response

Hugo Geerts, Athan Spiros, Anthony A. Grace, 2012, PloS one.

A Quantitative Systems Pharmacology Computer Model for Schizophrenia Efficacy and Extrapyramidal Side Effects

Hugo Geerts, Athan Spiros, H. Geerts, 2012 .

Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacology

Hugo Geerts, Athan Spiros, H. Geerts, 2015, Front. Pharmacol..

Predicting parkinsonism side-effects of antipsychotic polypharmacy prescribed in secondary mental healthcare

H. Geerts, R. Hayes, G. Kadra, 2018, Journal of psychopharmacology.

Impact of amyloid-beta changes on cognitive outcomes in Alzheimer’s disease: analysis of clinical trials using a quantitative systems pharmacology model

Hugo Geerts, Athan Spiros, H. Geerts, 2018, Alzheimer's Research & Therapy.

Multi-scale Modeling of Drug Action in the Nervous System

Robert Carr, Athan Spiros, Hugo Geerts, 2016 .

A quantitative way to estimate clinical off-target effects for human membrane brain targets in CNS research and development

Hugo Geerts, Athan Spiros, H. Geerts, 2012, Journal of experimental pharmacology.

Exploring the relation between BOLD fMRI and cognitive performance using a computer-based quantitative systems pharmacology model: Applications to the COMTVAL158MET genotype and ketamine

H. Geerts, A. Spiros, P. Roberts, 2021, European Neuropsychopharmacology.

Failure analysis of dimebon using mechanistic disease modeling: Lessons for clinical development of new Alzheimer's disease therapies

H. Geerts, A. Spiros, P. Roberts, 2012, Alzheimer's & Dementia.

Not all partial dopamine D 2 receptor agonists are the same in treating schizophrenia. exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse

H. Geerts, A. Spiros, R. Carr, 2010 .

Quantitative systems pharmacology as an extension of PK/PD modeling in CNS research and development

Hugo Geerts, Robert Carr, Athan Spiros, 2013, Journal of Pharmacokinetics and Pharmacodynamics.

Has the Time Come for Predictive Computer Modeling in CNS Drug Discovery and Development?

H Geerts, A Spiros, P Roberts, 2012, CPT: pharmacometrics & systems pharmacology.

EXPLORING THE BIOLOGY OF ILOPERIDONE RESPONDER PROFILES IN TREATMENT OF SCHIZOPHRENIA USING A MECHANISTIC DISEASE MODEL

H. Geerts, A. Spiros, R. Carr, 2010, Schizophrenia Research.

A COMPUTER MODEL THAT SIMULATE THE EFFECT OF TAU ANTIBODIES ON THE INTER-CELLULAR SPREAD OF TAU

H. Geerts, A. Jeromin, M. Haas, 2019, Alzheimer's & Dementia.

Galantamine benefits in Alzheimer's disease are related to increases in dopamine output

H. Geerts, M. Lazarewicz, A. Spiros, 2003, Schizophrenia Research.